The 25th JFCR-ISCC

December 8-9, 2021
Hybrid Meeting (On Site and Zoom)
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan

December 8

12:00-

Poster viewing

12:00-12:30

Committee meeting

Opening Remark

12:50-13:00

Naoya Fujita (Cancer Chemotherapy Center)

Opening remark

I New frontiers in CAR-mediated cancer immunotherapy

Chairpersons: Bob Valamehr (Fate Therapeutics Inc, San Diego, CA, USA),
Shunji Takahashi (JFCR, Tokyo)

13:00-13:40

Bob Valamehr (Fate Therapeutics Inc, San Diego, CA, USA)

iPSC-derived, multiplexed engineered CAR NK and T cell products targeting hematological and solid tumors

13:40-14:05

Shin Kaneko (CiRA, Kyoto Univ., Kyoto)

Induced pluripotent stem cell-derived immune cells for CAR-based cancer immunotherapy.

14:05-14:30

Yuki Kagoya (Aichi Cancer Ctr., Aichi)

Future perspectives of CAR-T cell therapy for cancer

14:30-14:40

Discussion

14:40-14:50

Break

Poster Flash Talks

Chairperson: Tetsuo Mashima (JFCR, Tokyo)

14:50-16:00

Toshifumi Hoki (MSD K.K., Tokyo)

Preclinical Characterization of a First-in-class ILT4 Antagonist, MK-4830

Hirofumi Mikami (Chugai Pharmaceutical Co., Ltd., Kanagawa)

Combination efficacy of STA551, a novel CD137 agonist activated by extracellular ATP, with immune targeted therapy

Masashi Numata (Daiichi Sankyo Co., Ltd., Tokyo)

Characterization of a novel menin-MLL inhibitor

Shotaro Nagase (Daiichi Sankyo Co., Ltd., Tokyo)

DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models

Toshihide Nishibata (Astellas Pharma Inc., Ibaraki)

Combination of Zolbetuximab with chemotherapeutic agents or anti-mPD-1 antibody improved antitumor effect in syngeneic immune-competent mice

Kazuharu Kamachi (Saga University, Saga)

The development of oral demethylating agent, OR-2100, and its impact on chronic myeloid leukemia

Naoya Nagaya (Juntendo University Graduate School of Medicine, Tokyo)

The United States of America-Japan drug lag in urological cancer treatment: the pre-approval use of Enfortumab vedotin for a third-line treatment of advanced bladder cancer in Japan.

Tomokazu Ohishi (Institute of Microbial Chemistry, Shizuoka)

Anti-metastatic activity of an anti-EGFR monoclonal antibody against metastatic colorectal cancer with KRAS p.G13D mutation

Masahiro Yasunaga (National Cancer Center, Chiba)

Development of next generation antibody therapeutics utilizing DDS and molecular imaging

Satoshi Kawano (Eisai Co., Ltd., Ibaraki)

Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models

Satoshi Takagi (Cancer Chemotherapy Center, JFCR, Tokyo)

Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma

Sho Isoyama (Cancer Chemotherapy Center, JFCR, Tokyo)

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

 


II New targets and strategies for maximizing the therapeutic outcomes

Chairpersons: Martijn P. Lolkema (Erasmus Univ. Medical Ctr., Rotterdam, Netherlands),
Shingo Dan (JFCR, Tokyo)

16:00-16:25

Ryohei Katayama (JFCR, Tokyo)

Potential therapeutic strategies for overcoming intrinsic and acquired resistance in ALK+NSCLC

16:25-17:05

Martijn P. Lolkema (Erasmus Univ. Medical Ctr., Rotterdam, Netherlands)

Large scale genomic analyses of metastatic cancer from biomarker discovery to patient selection for drug treatment

17:05-17:30

Tomohiro Yamaguchi (MSD, Tokyo)

Development of a first-in-class HIF-2α inhibitor, MK-6482

17:30-17:40

Discussion

17:40-17:50

Break

Meet-the-Expert Session

Chairperson: Mikihiko Naito (Tokyo Univ., Tokyo)

17:50-18:30

Paul Workman (Inst. Cancer Res., London, UK)

Discovery of innovative new cancer drugs and chemical probes for probing cancer biology and target validation

18:30-18:40

Discussion

December 9

III The next stage of cancer immune and antibody therapies

Chairpersons: Lillian Siu (Princess Margaret Cancer Ctr., Toronto, Canada),
Shigehisa Kitano (JFCR, Tokyo)

8:00-8:25

Mika Kamata-Sakurai (Chugai Pharmaceutical, Co., Ltd., Kanagawa)

A novel tumor selective anti-CD137 agonist antibody activated by elevated extracellular ATP in tumor microenvironment

8:25-9:05

Seema Gorla (Astellas, Glenview, IL , USA)

An overview of the enfortumab vedotin development program

9:05-9:45

Lillian Siu (Princess Margaret Cancer Ctr., Toronto, Canada)

Applications of ctDNA beyond genotyping – e.g., determination of molecular residual disease, predicting IO response

9:45-10:10

Yosuke Togashi (Okayama Univ., Okayama)

Cancer immunogenomics for the next stage of precision medicine

10:10-10:20

Discussion

10:20-10:30

Break

IV Blocking KRAS driver mutants and its acquired resistance

Chairpersons: Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA),
Seiji Yano (Kanazawa Univ., Kanazawa)

10:30-11:10

Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA)

Clinical acquired resistance to KRASG12C inhibition

11:10-11:35

Hiromichi Ebi (Aichi Cancer Ctr. Res. Inst., Aichi)

Targeting mutant KRAS based on its dependency in cancer cell survival

11:35-12:15

James G Christensen (Mirati Therapeutics, San Diego, CA, USA)

Adagrasib/MRTX849 and a KRAS G12D inhibitor, MRTX1133

12:15-12:25

Discussion

12:25-12:35

Break

Special Lecture

Chairpersons: Masanobu Oshima (Kanazawa Univ., Kanazawa),
Hiroshi Harada (Kyoto Univ., Kyoto)

12:35-13:25

William Kaelin (Dana-Farber Cancer Institute, Boston, MA, USA)

(Re)emerging principles of cancer therapy

13:25-13:35

Discussion

Closing Remark

13:35-13:50

Hiroyuki Seimiya (JFCR, Tokyo)

Closing remark

Poster viewing

-15:00

Page TOP